Core diagnostics, announced the official launch of its four high end cancer diagnostic tests for precise diagnosis in the areas of cervical, ovarian, brain tumors and hematological disorders, on the eve of the first Indian Cancer Congress (ICC 2013) in Delhi.
Launched by the names ovaCORE, cerviCORE, hemaCORE, neuroCORE, these tests aim to bring in high precision, said Zoya Brar, Co-Founder & MD, CORE Diagnostics. A lung cancer detection test for early detection of lung cancer on sputum sample was also introduced to Core’s portfolio at the time.
Brar pointed out that majority of these tests such as lung cancer detection test, NGS based tests like HLA typing in hemaCORE are not available in India, and the other common tests that are available have extremely long turnaround times.
While the lung cancer test introduced is completely non-invasive, the test meant for haematological disorders would cater to bone marrow transplant patients, newly diagnosed cases as well as for monitoring diagnosed cases. Tests for cervical and ovarian cancers will look at gynaecological cancer screening, diagnosis, prognosis and treatment.
“The cutting edge factor for all these tests is the case review by the US experts which would help the Indian physicians to provide their patients with global standards of care in India itself. It is a unique feature of our offerings,” Brar added.
As per WHO Report 2005, the estimated cancer deaths in India are projected to increase to 7 lakh by 2015. The burden of cancer is expected to further increase owing to increase in life expectancy, demographic transitions and the effects of tobacco and other risk factor.
EH News Bureau
